NO20061207L - Karboksylsyreforbindelser og medisinske preparater inneholdende de samme som den aktive bestanddel - Google Patents

Karboksylsyreforbindelser og medisinske preparater inneholdende de samme som den aktive bestanddel

Info

Publication number
NO20061207L
NO20061207L NO20061207A NO20061207A NO20061207L NO 20061207 L NO20061207 L NO 20061207L NO 20061207 A NO20061207 A NO 20061207A NO 20061207 A NO20061207 A NO 20061207A NO 20061207 L NO20061207 L NO 20061207L
Authority
NO
Norway
Prior art keywords
itching
receptors
urticaria
inflammation
disease
Prior art date
Application number
NO20061207A
Other languages
English (en)
Inventor
Fumio Nambu
Atsushi Naganawa
Maki Iwahashi
Kaoru Kobayashi
Atsushi Kinoshita
Atsushi Shimabukuro
Seiji Ogawa
Koji Yano
Yutaka Okada
Yoko Kishida
Shouji Kawauchi
Kohki Tsukamoto
Yoko Matsunaga
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Publication of NO20061207L publication Critical patent/NO20061207L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Nutrition Science (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)

Abstract

Forbindelser representert ved den etterfølgende generelle formel (I): (I) hvori hvert symbol er som definert i beskrivelsen; salter derav, solvater derav eller prodruger derav som binder til DP reseptorer og antagoniserer disse. De er derfor anvendbare for å forebygge og/eller behandle allergiske sykdommer (allergisk nefritt, allergisk konjunktivitt, atopisk dermatitt, bronkialastma, matallergi osv.), systemisk mastcelle-sykdom, systemisk mastcelle-aktiveringslidelse, anafylaktisk sjokk, luftveiskontraksjon, urtikaria, eksem, sykdommer med kløe (atopisk dermatitt, urtikaria osv.), sekundære sykdommer (katarakt, retinal atskillelse, inflammasjon, infeksjon, søvnforstyrrelse, osv.) bevirket ved opptreden forbundet med kløing (kloring, slåing, osv.), inflammasjon, kronisk obstruktiv pulmonal sykdom, iskemisk reperfusjonsskade, cerebrovaskulære lidelser, revmatoid artritt, pleuritt, ulcerøs kolitt og så videre. På grunn av spesifikk binding til DP reseptorer men kun svak binding til andre prostaglandinreseptorer, muliggjør de ovennevnte forbindelser fremstillingen av legemidler med små bivirkninger.
NO20061207A 2003-09-17 2006-03-15 Karboksylsyreforbindelser og medisinske preparater inneholdende de samme som den aktive bestanddel NO20061207L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003325198 2003-09-17
JP2004101863 2004-03-31
PCT/JP2004/013983 WO2005028455A1 (ja) 2003-09-17 2004-09-16 カルボン酸化合物およびそれらを有効成分として含有する医薬組成物

Publications (1)

Publication Number Publication Date
NO20061207L true NO20061207L (no) 2006-06-19

Family

ID=34380314

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20061207A NO20061207L (no) 2003-09-17 2006-03-15 Karboksylsyreforbindelser og medisinske preparater inneholdende de samme som den aktive bestanddel

Country Status (18)

Country Link
US (2) US7601712B2 (no)
EP (1) EP1666473B1 (no)
JP (1) JP4919143B2 (no)
KR (1) KR20060080197A (no)
AU (1) AU2004274324B2 (no)
BR (1) BRPI0414487A (no)
CA (1) CA2539070C (no)
DK (1) DK1666473T3 (no)
ES (1) ES2399393T3 (no)
IL (1) IL174336A (no)
MX (1) MXPA06002945A (no)
NO (1) NO20061207L (no)
NZ (1) NZ545934A (no)
PL (1) PL1666473T3 (no)
PT (1) PT1666473E (no)
RU (1) RU2375353C2 (no)
TW (1) TWI341838B (no)
WO (1) WO2005028455A1 (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120035220A (ko) * 2003-01-22 2012-04-13 센주 세이야꾸 가부시키가이샤 안질환 치료용 경피 흡수형 제제, 그 사용, 및 안질환 치료약의 눈의 국소 조직으로의 이행 방법
PT2037967T (pt) * 2006-06-16 2017-03-14 Univ Pennsylvania Antagonistas do recetor de prostaglandina d2 para o tratamento da alopecia androgenética
FR2903985B1 (fr) 2006-07-24 2008-09-05 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
TWI410410B (zh) 2007-08-10 2013-10-01 Ono Pharmaceutical Co Phenylacetic acid compounds
DE102008059133A1 (de) 2008-11-26 2010-05-27 Merck Patent Gmbh Difluorphenyl-diacylhydrazid-derivate
WO2016001452A1 (en) 2014-07-04 2016-01-07 Universität Zürich Compounds, in particular for use in the treatment of a disease or condition for which a bromodomain inhibitor is indicated
RU2626829C2 (ru) * 2015-11-02 2017-08-02 Анатолий Тимофеевич Корабельников Средство для лечения полипов в пазухах носа и для предотвращения их повторного нарастания, а также способ его применения
TWI822457B (zh) * 2018-09-20 2023-11-11 日商小野藥品工業股份有限公司 Ｄｐ拮抗劑
WO2021187547A1 (ja) * 2020-03-19 2021-09-23 小野薬品工業株式会社 フェニル酢酸化合物の結晶
JP7047954B2 (ja) * 2020-03-19 2022-04-05 小野薬品工業株式会社 フェニル酢酸化合物を含有する医薬組成物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5764655A (en) * 1980-10-04 1982-04-19 Nippon Zoki Pharmaceut Co Ltd Novel benzoylaminophenylcarboxylic acid derivative, its preparation, and drug composition comprising it
EP0218728A1 (en) * 1985-04-03 1987-04-22 Yamanouchi Pharmaceutical Co. Ltd. Phenylene derivatives
JP4292742B2 (ja) 2000-03-09 2009-07-08 小野薬品工業株式会社 インドール誘導体、その製造方法および用途
JP4547913B2 (ja) * 2002-03-19 2010-09-22 小野薬品工業株式会社 カルボン酸化合物およびその化合物を有効成分として含有する薬剤
AU2003227325B2 (en) * 2002-08-02 2009-05-28 Scientific Games, Llc Lottery ticket security method
EP1591441A4 (en) * 2003-02-07 2007-10-31 Ono Pharmaceutical Co CARBON ACID COMPOUNDS
WO2004099170A2 (en) 2003-04-30 2004-11-18 The Institutes For Pharmaceutical Discovery, Llc Phenyl substituted carboxylic acids as inhibitors of protein tyrosine phosphatase-1b

Also Published As

Publication number Publication date
PL1666473T3 (pl) 2013-05-31
RU2375353C2 (ru) 2009-12-10
CA2539070C (en) 2011-12-13
EP1666473A4 (en) 2009-06-03
EP1666473A1 (en) 2006-06-07
PT1666473E (pt) 2013-02-15
TWI341838B (en) 2011-05-11
TW200524886A (en) 2005-08-01
NZ545934A (en) 2009-05-31
AU2004274324A1 (en) 2005-03-31
US20070004716A1 (en) 2007-01-04
US8138335B2 (en) 2012-03-20
EP1666473B1 (en) 2013-01-02
WO2005028455A1 (ja) 2005-03-31
MXPA06002945A (es) 2006-06-14
US20100029631A1 (en) 2010-02-04
ES2399393T3 (es) 2013-04-01
IL174336A (en) 2012-01-31
IL174336A0 (en) 2006-08-01
BRPI0414487A (pt) 2006-11-14
US7601712B2 (en) 2009-10-13
DK1666473T3 (da) 2013-03-25
JP4919143B2 (ja) 2012-04-18
RU2006112573A (ru) 2007-10-27
AU2004274324B2 (en) 2009-11-05
CA2539070A1 (en) 2005-03-31
JPWO2005028455A1 (ja) 2006-11-30
KR20060080197A (ko) 2006-07-07

Similar Documents

Publication Publication Date Title
NO20061207L (no) Karboksylsyreforbindelser og medisinske preparater inneholdende de samme som den aktive bestanddel
NO20024281L (no) Indolderivater, fremgangsmÕte for fremstilling av de samme og anvendelse derav
NO20084291L (no) 2,6-substituert-4-monosubstituert aminopyridin som prostaglandin D2 reseptor-antagonister
NO20074336L (no) 2-fenylindoler som prostaglandin D2 reseptorantagonister
NO20090862L (no) 2-fenyl-indoler som prostaglandin D2-reseptorantagonister
WO2005021515A3 (en) Inhibitors of phosphodiesterase type-iv
RU2008118491A (ru) Первичная кислая фосфатная соль антагониста рецептора простагландина d2
UA88485C2 (en) 2,6-substituted-4-monosubstituted amino-pyrimidines as prostaglandin d2 receptor antagonists
WO2014037342A1 (de) Herbizid wirksame bicycloarylcarbonsäureamide
WO2006085212A3 (en) Condensed isoxaline derivatives as inhibitors of phosphodiesterase type-iv
NO20043894L (no) Karboksysyreforbindelser og legemidler inneholdende forbindelsene som den aktive bestanddel
EA200900472A1 (ru) Ингибиторы фосфодиэстеразы iv типа
WO2007102883A3 (en) Chemical compounds
TW200635932A (en) New pyridothienopyrimidine derivatives
NO20080457L (no) Kjemiske forbindelser
EP2928887A1 (de) N-(oxazol-2-yl)-arylcarbonsäureamide und ihre verwendung als herbizide
EP2844650A1 (de) 6-pyridon-2-carbamoyl-azole und ihre verwendung als herbizide
WO2005051931A3 (en) Phosphodiesterase inhibitors
WO2006129158A3 (en) 3 - indazolyl - isoxazoline derivatives as inhibitors of phosphodiesterase type - i
WO2015007633A1 (de) 6-azinon-2-carbonyl-derivate und ihre verwendung als herbizide
UA95303C2 (en) 2-phenyl-indoles as prostaglandin d2 receptor antagonists
TH106955A (th) 2-เฟนิล-อินโดล ที่เป็นกลุ่มสารต้านตัวรับพรอสตาแกลนดิน d2
WO2008035316A3 (en) Phosphodiesterase inhibitors
WO2007046022A3 (en) Inhibitors of phosphodiesterase type-iv
TH84867A (th) สารประกอบเฮทเทอโรไซคลิคใหม่ที่เป็นประโยชน์สำหรับการรักษาความผิดปกติทางการอักเสบและทางด้านภูมิแพ้

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application